COX-2 inhibition: a possible role in the management of prostate cancer?
There is mounting evidence to support a role for cyclooxygenase-2 (COX-2) inhibitors (coxibs) in the management of prostate cancer. This review considers the current evidence base for the use of coxibs in prostate cancer as well as their adverse event profile. A systematic literature review using th...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2007
|
| _version_ | 1797057717791096832 |
|---|---|
| author | Sooriakumaran, P Langley, SE Laing, R Coley, H |
| author_facet | Sooriakumaran, P Langley, SE Laing, R Coley, H |
| author_sort | Sooriakumaran, P |
| collection | OXFORD |
| description | There is mounting evidence to support a role for cyclooxygenase-2 (COX-2) inhibitors (coxibs) in the management of prostate cancer. This review considers the current evidence base for the use of coxibs in prostate cancer as well as their adverse event profile. A systematic literature review using the search terms 'cyclooxygenase', 'COX-2', 'coxibs', 'cardiovascular risk', and 'prostate cancer' was performed using Medline. Celecoxib appears safer in terms of cardiovascular toxicity than other coxibs, and this may relate to its lower selectivity for the COX-2 enzyme. This lower selectivity also provides rationale for its putative broader anti-cancer effects, via non-COX-2-dependent pathways that affect cell cycle regulation, angiogenesis, and hypoxic modulation. There are also interacting relationships between COX-2, chronic inflammation, and prostate cancer. There is much promise for the coxibs as anti-cancer agents. The future might be to pharmacologically adapt these agents to exert their COX-2 independent mechanisms of action while minimizing their COX-2-dependent adverse cardiovascular effects. |
| first_indexed | 2024-03-06T19:40:23Z |
| format | Journal article |
| id | oxford-uuid:207579b3-46a6-431e-86bc-7fd91cef23af |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:40:23Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:207579b3-46a6-431e-86bc-7fd91cef23af2022-03-26T11:27:46ZCOX-2 inhibition: a possible role in the management of prostate cancer?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:207579b3-46a6-431e-86bc-7fd91cef23afEnglishSymplectic Elements at Oxford2007Sooriakumaran, PLangley, SELaing, RColey, HThere is mounting evidence to support a role for cyclooxygenase-2 (COX-2) inhibitors (coxibs) in the management of prostate cancer. This review considers the current evidence base for the use of coxibs in prostate cancer as well as their adverse event profile. A systematic literature review using the search terms 'cyclooxygenase', 'COX-2', 'coxibs', 'cardiovascular risk', and 'prostate cancer' was performed using Medline. Celecoxib appears safer in terms of cardiovascular toxicity than other coxibs, and this may relate to its lower selectivity for the COX-2 enzyme. This lower selectivity also provides rationale for its putative broader anti-cancer effects, via non-COX-2-dependent pathways that affect cell cycle regulation, angiogenesis, and hypoxic modulation. There are also interacting relationships between COX-2, chronic inflammation, and prostate cancer. There is much promise for the coxibs as anti-cancer agents. The future might be to pharmacologically adapt these agents to exert their COX-2 independent mechanisms of action while minimizing their COX-2-dependent adverse cardiovascular effects. |
| spellingShingle | Sooriakumaran, P Langley, SE Laing, R Coley, H COX-2 inhibition: a possible role in the management of prostate cancer? |
| title | COX-2 inhibition: a possible role in the management of prostate cancer? |
| title_full | COX-2 inhibition: a possible role in the management of prostate cancer? |
| title_fullStr | COX-2 inhibition: a possible role in the management of prostate cancer? |
| title_full_unstemmed | COX-2 inhibition: a possible role in the management of prostate cancer? |
| title_short | COX-2 inhibition: a possible role in the management of prostate cancer? |
| title_sort | cox 2 inhibition a possible role in the management of prostate cancer |
| work_keys_str_mv | AT sooriakumaranp cox2inhibitionapossibleroleinthemanagementofprostatecancer AT langleyse cox2inhibitionapossibleroleinthemanagementofprostatecancer AT laingr cox2inhibitionapossibleroleinthemanagementofprostatecancer AT coleyh cox2inhibitionapossibleroleinthemanagementofprostatecancer |